Reviva Pharmaceuticals Holdings, Inc. Common Stock
RVPH Real Time Price USDRecent trades of RVPH by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by RVPH's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
Estimated quarterly lobbying spending
RVPH Revenue by Segment or Geography
New patents grants
-
Patent Title: Methods for treating pulmonary fibrosis Aug. 06, 2024
-
Patent Title: Methods for treating pulmonary hypertension Oct. 15, 2019
-
Patent Title: Arylpiperazine derivatives and methods of utilizing same May. 22, 2018
-
Patent Title: Methods for treating attention deficit hyperactivity disorder Mar. 06, 2018
-
Patent Title: Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives Jul. 04, 2017
-
Patent Title: Arylpiperazine derivatives and methods of utilizing same Mar. 28, 2017
-
Patent Title: Synthesis, methods of using, and compositions of cycloalkylmethylamines Apr. 05, 2016
-
Patent Title: Cycloalkylmethylamines Mar. 29, 2016
-
Patent Title: Arylpiperazine derivatives and methods of utilizing same Feb. 09, 2016
-
Patent Title: Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives Jan. 19, 2016
-
Patent Title: Methods of using cycloalkylmethylamine derivatives Aug. 04, 2015
-
Patent Title: Arylpiperazine derivatives and methods of utilizing same Mar. 17, 2015
-
Patent Title: Methods of utilizing arylpiperazine derivatives Oct. 14, 2014
-
Patent Title: Synthesis, methods of using, and compositions of cycloalkylmethylamines Mar. 11, 2014
-
Patent Title: Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives Dec. 10, 2013
-
Patent Title: Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors Nov. 12, 2013
-
Patent Title: Compositions, synthesis, and methods of utilizing quinazolinedione derivatives Nov. 05, 2013
-
Patent Title: Methods of utilizing arylpiperazine derivatives Jun. 11, 2013
-
Patent Title: Cycloalkylmethylamines May. 21, 2013
-
Patent Title: Methods of utilizing arylpiperazine derivatives Apr. 30, 2013
-
Patent Title: Methods of using cycloalkylmethylamines Feb. 12, 2013
-
Patent Title: Cycloalkylmethylamines Dec. 25, 2012
-
Patent Title: Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors Aug. 21, 2012
-
Patent Title: Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents Aug. 21, 2012
-
Patent Title: Compositions, synthesis, and methods of using piperazine based antipsychotic agents Jun. 26, 2012
-
Patent Title: Compositions, synthesis, and methods of utilizing arylpiperazine derivatives May. 29, 2012
-
Patent Title: Synthesis, methods of using, and compositions of cycloalkylmethylamines Aug. 02, 2011
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to RVPH
Recent picks made for RVPH stock on CNBC
ETFs with the largest estimated holdings in RVPH
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $RVPH stock a Buy, Sell, or Hold?
- What is the price target for $RVPH stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $RVPH stock?
- Who owns the most shares of $RVPH stock?
- What funds own $RVPH stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view RVPH Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.
- Address Cupertino, CA
- Market Cap 36.7 million
- Employees 14
- Industrial Classification Pharmaceutical Preparations